SCHEDULE: Vanguard Amends Edwards Lifesciences Ownership Report

The Vanguard Group filed an amendment to its Schedule 13G for Edwards Lifesciences Corp, reporting zero beneficial ownership following an internal realignment.

Summary

• The Vanguard Group filed an Amendment No. 16 to its Schedule 13G for Edwards Lifesciences Corp.
• The filing indicates that The Vanguard Group now holds 0% beneficial ownership of Edwards Lifesciences Corp Common Stock, with 0 shares in sole or shared voting and dispositive power.
• This change is a result of an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of Vanguard will report beneficial ownership separately (on a disaggregated basis) in reliance on SEC Release No. 34-39538 (January 12, 1998).
• The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by these subsidiaries and/or business divisions.
• These subsidiaries and/or business divisions will continue to pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. It is an administrative update regarding beneficial ownership reporting by The Vanguard Group, not a reflection of Edwards Lifesciences' operational or financial performance.

Future Outlook

The Vanguard Group's future beneficial ownership reporting will be conducted on a disaggregated basis by its subsidiaries and/or business divisions, in accordance with SEC guidelines.

Management Comments

• "On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release."
• "These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment."
• "Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions."

Industry Context

StockSavvy.ai notes this filing reflects an internal administrative and compliance adjustment by a major asset manager, The Vanguard Group, regarding its beneficial ownership reporting structure. It is not indicative of a change in investment strategy for Edwards Lifesciences Corp or broader industry trends affecting the medical technology sector, but rather a procedural update in line with SEC regulations for large institutional investors.

Corporate Governance

Stakeholder Impact

• Shareholders of Edwards Lifesciences Corp: Minimal direct impact, as the underlying investment strategies of Vanguard's managed funds remain unchanged; only the reporting entity for beneficial ownership has shifted.
• The Vanguard Group: The realignment streamlines compliance with SEC reporting requirements by disaggregating beneficial ownership reporting among its internal entities.

Next Steps

• Vanguard's subsidiaries and/or business divisions will continue to report beneficial ownership separately on a disaggregated basis.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Vanguard Group, Edwards Lifesciences, SEC Filing, Internal Realignment, Disaggregated Reporting